Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-26T19:11:14.141Z Has data issue: false hasContentIssue false

60 - Ezogabine

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Potiga

Generic?

• No

Class

• Antiepileptic drug (AED)

Commonly Prescribed for

(FDA approved in bold)

Adjunctive treatment of partial-onset seizures in patients ≥ 18 years old who have responded inadequately to several alternative treatments and for whom the benefits outweigh the risk of retinal abnormalities and potential decline in visual acuity

How the Drug Works

• Ezogabine stabilizes the resting membrane potential and reduces brain excitability by keeping transmembrane potassium channels (KCNQ2, KCNQ3) open longer and delaying membrane repolarization (stabilizes M-current resting membrane potential). It may also potentiate GABAA receptors

How Long Until It Works

• Tmax 0.5–2 hours. Clinical effects may take weeks to months

If It Works

• Periodic ophthalmological and urological monitoring. May consider tapering after seizure free for 2 years, depending on the seizure type

If It Doesn't Work

• Consider changing to another agent, adding a second agent, using a medical device, or a referral for epilepsy surgery evaluation. When adding a second agent, keep drug interactions in mind

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Not available

Tests

• No test required

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Affecting potassium channels in brain and bladder

Notable AEs

• Urinary retention (2%), skin discoloration (lips, nail beds, etc.), neuropsychiatric symptoms (confusion, psychosis, hallucination), dizziness, somnolence, QTc prolongation (7.7 ms at 1200 mg/day), withdrawal seizure, abuse potential

Life-Threatening or Dangerous AEs

• Retinal dystrophy (perivascular pigmentation, focal retinal epithelium clumping), vision loss, suicidal behavior

Weight Gain

• Common

• Dose-related weight gain

Sedation

• Not unusual

What to Do About AEs

• Discontinue and switch to another agent

Best Augmenting Agents to Reduce AEs

• Alcohol worsens the adverse reaction

DOSING AND USE

Usual Dosage Range

• 600–1200 mg 3 times daily, with or without food, swallowed whole

Dosage Forms

• Tablets: 50, 200, 300, and 400 mgagents or antineoplastic agents

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 223 - 225
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Ezogabine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.061
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Ezogabine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.061
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Ezogabine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.061
Available formats
×